Pleiotrophin (PTN) is a 136-amino acid secreted heparinbinding protein that is considered as a rate-limiting growth and an angiogenic factor in the onset, invasion, and metastatic process of many tumors. Its mitogenic and tumorigenic activities are mediated by the COOH-terminal residues 111 to 136 of PTN, allowing it to bind to cell surface tyrosine kinase-linked receptors. We investigated a new strategy consisting in evaluating the antitumor effect of a truncated PTN, lacking the COOH-terminal 111 to 136 portion of the molecule (PTN#111-136), which may act as a dominant-negative effector for its mitogenic, angiogenic, and tumorigenic activities by heterodimerizing with the wild-type protein. In vitro studies showed that PTN#111-136 selectively inhibited a PTN-dependent MDA-MB-231 breast tumor and endothelial cell proliferation and that, in MDA-MB-231 cells expressing PTN#111-136, the vascular endothelial growth factor-A and hypoxia-inducible factor-1A mRNA levels were significantly decreased by 59% and 71%, respectively, compared with levels in wild-type cells. In vivo, intramuscular electrotransfer of a plasmid encoding a secretable form of PTN#111-136 was shown to inhibit MDA-MB-231 tumor growth by 81%. This antitumor effect was associated with the detection of the PTN#111-136 molecule in the muscle and tumor extracts, the suppression of neovascularization within the tumors, and a decline in the Ki-67 proliferative index. Because PTN is rarely found in normal tissue, our data show that targeted PTN may represent an attractive and new therapeutic approach to the fight against cancer.
Introduction
Tumor progression and metastasis depend on angiogenesis, a process inducing the outgrowth of new blood vessels from preexisting vessels (1) . This process implies the presence of multiple controls and especially the upregulation of growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, which are capable of inducing the activation and expansion of endothelial cells. More recently, new growth factor members of the heparin-binding growth factor family such as pleiotrophin (PTN) and midkine (MDK) have been described, which also contribute to promoting tumorigenesis and angiogenesis. PTN was shown to induce the proliferation and migration of endothelial cells in vitro (2 -6) and has been correlated with enhanced tumor growth and vascular density in vivo (5, 6) . PTN was shown to be particularly involved in tumor growth of several cancer types (4, 7) and to also display transforming activity (8) .
PTN is an 18-kDa secreted polypeptide of 136 amino acids, containing a heparin-binding site that plays a role in the modulation of PTN mitogenic activity (2) and in dimerization of the molecule (9) .
Several PTN receptors have been described. In contrast to the members of the low-density lipoprotein receptorrelated protein family (10) that are considered to be exclusively receptors of MDK (11) , members of the proteoglycans including the receptor protein-tyrosine phosphatase (RPTP) have been assigned as the receptors of PTN involved in the migration and adhesion of tumor and endothelial cells (12) . It has been shown that PTN binds to the extracellular RPTPh/~domain 6B4 proteoglycan/ phosphacan (13) . Recently, it has been shown that this interaction was mediated by the COOH-terminal part of PTN involving 10 amino acids of the COOH-terminal part of PTN called P122-131 (14) .
Anaplastic lymphoma kinase is one of the major tyrosine kinase receptors of PTN, which induces the phosphorylation and recruitment of downstream effector molecules such as IRS-1, Shc, phospholipase Cg, and phosphatidylinositol 3-kinase (15, 16) . It has been shown that PTN binds to the extracellular domain of ALK via its COOH-terminal domain and that PTN lacking its COOH terminus is unable to interact with ALK, thus showing the importance of the COOH-terminal residues of PTN for its mitogenic and tumorigenic activities (2, 17) . Subsequently, a synthetic peptide corresponding to the deleted 26 amino acids residues of the COOH terminus of PTN, designated P111-136, has been shown to bind to the extracellular domain of ALK and to inhibit PTN-induced mitogenesis (2, 17) . Furthermore, it has been shown that, when PTN is lacking its last 26 amino acids (PTND111-136), it plays a dominantnegative effector for its mitogenic, angiogenic, and transforming activities by heterodimerizing with the wild-type protein (2) .
In this study, we assessed the in vivo activities of the 111-136-deleted PTN and show for the first time that this truncated protein could act as a potent inhibitor of tumor growth and angiogenesis in an MDA-MB-231 breast carcinoma model. Furthermore, we focused our study on the mechanism of action of the PTN-deleted protein, which allowed us to explain the inhibition of PTN biological activities.
Materials and Methods
Plasmid DNA The pcDNA3-LacZ plasmid was obtained by cloning the LacZ fragment (isolated from the PvaxLacZ plasmid) between the EcoRI and the NotI sites of the pcDNA3.1 plasmid (Invitrogen). The pcDNA3-PTND111-136 (2), pcDNA3-LacZ, and pcDNA-HSA plasmids were purified using endofree Plasmid Maxi Kit (Qiagen) and solubilized in endotoxin-free 0.9% NaCl at working concentrations.
Cell Culture and Conditioned Medium Human umbilical vein endothelial cells (HUVEC), human microvascular endothelial cells (HMEC-1), PC3 cells (ATCC CRL1435), MDA-MB-231 cells (ATCC HTB26), MCF-7 cells (ATCC HTB22), and stably transfected MDA-MB-231 cells expressing PTND111-136 (MDA-MB-231-PTND111-136) were cultured as described previously (2, 18) . U138MG glioblastoma cell lines (ATCC HTB16), U38MG astrocytoma cell lines (ATCC HTB14), and L6 cell lines (ATCC CRL1458) were grown in DMEM-fetal bovine serum and Jurkat human T-cell lines (ATCC HTB14) were grown in RPMI supplemented with 10% fetal bovine serum. The MDA-MB-231-GFP cells were obtained using a retrovirus vector encoding the green fluorescent protein (GFP) gene as described previously (19) . To produce conditioned medium containing the PTND111-136 protein, MDA-MB-231-PTND111-136 and L6 murine muscle cells were seeded onto six-well plates and grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum. Twenty-four hours later, L6 cells were transfected with 1 Ag pcDNA3-PTND111-136 plasmid using LipofectAMINE 2000 reagent (Invitrogen) according to the protocol recommended by the manufacturer during 4 days. The supernatants were harvested 96 h after the culture, aliquoted, and stored at À20jC until use. The supernatant of MDA-MB-231 and nontransfected cells were used as a control.
Small Interfering RNA The small interfering RNAs (siRNA) were purchased from Qiagen. The ALK (gene accession no. NM_004304) siRNA silencing sequence and the nonsilencing siRNA used as control were designed by Qiagen. siRNAs were transfected using Hiperfect (Qiagen) according to the manufacturer's instructions. U138MG cells were at 80% confluence and the final siRNA concentration was 5 nmol/L. The medium was changed 24 h after transfection and cells were collected after 5 days for Western blot analysis.
Flow Cytometry A coculture assay was done by mixing 1 Â 10 4 MDA-MB-231 or MDA-MB-231-PTND111-136 cells with 1 Â 10 4 MDA-MB-231-GFP cells. The cells were cultured in 12-well plates in the appropriate medium supplemented with 10% fetal bovine serum. After 24 h culture, GFP-positive cells were quantified using a fluorescence-activated cell sorting flow cytometer (Becton Dickinson).
Western Blot Analysis and ELISA The PTN expression in supernatants, cell pellets, and extracellular compartments defined as cell surface and extracellular matrix MDA-MB-231 tumors was done in MDA-MB-231 and PC3 cells by Western blot analysis following heparin Sepharose precipitation as described previously (20) . Quantification of the immunoreactive material was done by densitometric analysis using a ChemiGenius system and the Genetools software (Syngene). For ALK detection, proteins were transferred to nitrocellulose membrane that was blocked in TBS, 0.1% Tween 20, 5% powered milk and probed with rabbit anti-ALK antibody (1:7,000; Zymed). Goat anti-rabbit peroxidase-linked antibody (1:10,000; Promega) was used as secondary antibody. Actin was detected with monoclonal anti-h-actin peroxidase conjugate (1:50,000). The levels of PTN in cell supernatants were quantified by an ELISA test, using a goat anti-PTN antibody (R&D Systems), according to the procedure described previously (21) .
Real-time Reverse Transcription-PCR The theoretical and practical aspects of real-time quantitative reverse transcription-PCR (RT-PCR) using the ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems) as well as the RNA extraction method, cDNA synthesis, and PCR conditions were described in detail elsewhere (22) . Target gene expression was normalized relative to an endogenous RNA control (TBP gene, which encodes TATA box-binding protein) as described previously (23) . Results expressed as N-fold differences in target gene expression relative to the TBP gene and termed ''N Target '' were determined as N Target = 2
DCt sample , where the DCt value of the sample was determined by subtracting the average Ct value of the target gene from the average Ct value of the TBP gene. The 
Proliferation and Soft Agar Assays
Cells were seeded in 24-well tissue culture dishes at a density of 5 Â 10 4 per well for PC3, HUVEC, and HMEC-1 cells and 2 Â 10 4 per well for MDA-MB-231 and MCF-7 cells in complete medium. After 24 h, the medium was replaced by 420 AL fetal bovine serum-free medium and 280 AL L6 conditioned medium containing or not PTND111-136 or by 280 AL MDA-MB-231 or MDA-MB-231-PTND111-136 conditioned medium. The culture mediums were refreshed every 24 h over 4 days, and cell survival was then quantified by a cell proliferation assay using the 3-(4 ¶,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay as described previously (18) . A proliferation assay and a soft agar assay were done with MDA-MB-231 cells in the presence of 0.1 and 0.01 Amol/L anti-PTN antibody (R&D Systems) as described previously (24) .
Migration Assay
The migration assay was done using 24-well microchemotaxis Boyden chambers (Costar) with 8-Am pore polycarbonate membranes. The bottom chamber was filled with L6 conditioned medium and the upper chamber was loaded with 5 Â 10 5 HUVEC cells in 1 mL appropriate medium. After 24 h incubation, the membranes were fixed in acetone and cells were stained with May-GrunwaldGiemsa. Cells that had migrated through the membrane were quantified by counting eight fields of each membrane using a microscope with Â50 magnification.
Plasmid Electrotransfer Before the electrotransfer procedure, 6-week-old female athymic mice were anesthetized with an i.p. injection of 100 mg/kg ketamine (Ketalar, Panpharma) and 40 mg/kg xylazine (Rompun, Bayer). pcDNA3-PTND111-136 plasmid or controls (pcDNA3-LacZ and pcDNA3-HAS; 20 or 30 Ag) were resuspended in 30 AL sterile 0.9% normal saline and then injected into both tibialis cranialis muscles of mice using a Hamilton syringe. The three plasmids were then electrotransferred using a PS-15 electropulsator (Jouan) as described previously (25) .
Tumor Cell Inoculation MDA-MB-231, MDA-MB-231-PTND111-136, and PC3 cells were harvested, washed, and resuspended in sterile PBS and 4 Â 10 6 cells in 100 AL were injected s.c. 7 days after the plasmid electrotransfer into the posterior flank of nude mice.
The tumor size was monitored measuring the largest (a) and the longest (b) tumor diameters and the tumor volume was calculated using the following formula:
3 Â p / 6. The tumor size was monitored over 1 month after the injection of tumor cells. At completion of each experiment, mice were sacrificed using a lethal dose of isofluorane. For each mouse, the two tibialis cranialis muscles and the tumor were collected and stored for immunohistochemical analysis.
Immunohistochemistry and Image Analysis Muscles and tumors were fixed in FineFix (Milestone), and paraffin sections (4 Am thick) were prepared. Paraffin sections of MDA-MB-231 tumor cells were prepared to quantify the number of intratumor vessels by CD31 immunostaining and Ki-67 expression as described (18, 26, 27) . Paraffin sections of muscles were prepared to evaluate h-galactosidase expression as described (28) and PTND111-136 expression. For PTND111-136 staining, slides were first incubated with the anti-PTN antibody (R&D Systems) and then incubated with a biotin-conjugated rabbit anti-goat antibody (DAKO) and with the streptavidin/peroxidase horseradish peroxidase complex (DAKO).
Statistical Analysis Each experiment was done at least twice. Statistical significance was evaluated using the Student's t test (unilateral and unpaired). To evaluate the potential contribution of HBGH signaling, we then studied the expression of its receptors (ALK, RPTP, and lipoprotein receptor-related proteins) using real-time RT-PCR technology (see Materials and Methods). As shown in Fig. 1B , in contrast to U87MG positive for ALK, the amount of the ALK receptor transcripts was below detection in all extracts tested. An immunoblot analysis done on cell extracts from breast carcinoma cell lines (MDA-MB-231 expressing or not PTND111-136 and MCF-7) confirmed these results (Fig. 1C) . In contrast to Jurkat cells known to be ALK negative, two major isoforms of ALK were identified (220 and 140 kDa) in extracts from U38MG and U138MG cell lines that were undetectable when ALK was knocked down by siRNA in U138MG cells (Fig. 1D ). Concerning the RPTP and lipoprotein receptor-related protein profiles, most part of the breast tumor cells exhibited the mRNA of RPTPA and B (except MB468 and T47D) in contrast to the PC3 cell line, which expressed RPTPD, and RPTPS, which seems to be highly ubiquitous in all cells lines tested (Fig. 1B) . Furthermore, in contrast to PC3 cells, all breast cell lines exhibited the mRNA of LRP6 and some of them expressed also lipoprotein receptorrelated proteins 1h and 2.
Results

Expression of PTN and Its Receptors
In
vitro Expression and Functional Characterization of PTN#111-136
Experiments were first done to verify the expression and secretion of PTND111-136. The amount of PTND111-136 was evaluated with a specific ELISA. As shown in Fig. 2A , an expression level up to 13 ng/mL culture medium was obtained in pcDNA3-PTND111-136 L6 conditioned medium, whereas no signal was detected in the supernatant of nontransfected L6 (<1 ng/mL). After 96 h culture, MDA-MB-231 cells expressing PTND111-136 exhibited a high quantity of the secreted immunoreactive protein compared with the control cells (15.3 versus <1 ng/mL), confirming satisfactory expression of PTND111-136 by both cell lines.
To evaluate a potential role of PTND111-136 in inhibiting angiogenesis, an endothelial cell proliferation assay was first done. We thus assayed PTND111-136, produced by transfected L6 cells, for their inhibitory activity on immortalized human endothelial cells (HMEC-1) or primary human endothelial cells (HUVEC) in a 96 h proliferation assay using the MTT test. Under these conditions, endothelial cell proliferation was significantly inhibited by 51% and 31%, respectively, for HMEC-1 (P < 0.007) and HUVEC (P < 0.05) compared with the control (Fig. 2B) . As angiogenesis occurs through endothelial cell migration, it was therefore important to analyze whether PTND111-136 affects HUVEC cell migration or not using Boyden chambers. As shown in Fig. 2C and D, the migration of HUVEC was inhibited by 31% when medium containing PTND111-136 was added compared with the migration of cells grown in control medium (P < 0.0009). These results clearly show that PTND111-136 exerts inhibitory activity on the proliferation and the migration of primary endothelial cells.
We then evaluated the PTN autocrine loop using polyclonal anti-human PTN antibody in a proliferation assay (Fig. 3A, 1 ) and in a soft agar colony formation assay (Fig. 3A, 2 ) . Polyclonal anti-human PTN antibodies induced a significant dose-dependent decrease in colony formation and a significant inhibition of cell proliferation, whereas idiotypic immunoglobulins, used as the control, had no effect. These data clearly showed the existence of an autocrine PTN signaling loop for MDA-MB-231 cells. We thus did a proliferation assay using MDA-MB-231 in the presence of PTND111-136. As shown in Fig. 3B, 1 , 66% of MDA-MB-231 cell proliferation was abolished compared with that of the control (P < 0.003), whereas PC3 cells expressing lower level of PTN were not affected (P = 0.2) by PTND111-136 (Fig. 3B, 2) . To assess the paracrine effect of PTND111-136 produced by human cells, we used Fig. 3D , the cell proliferation was reduced for both cell lines and was more pronounced in MDA-MB-231 cells (70.3% of inhibition; P < 0.0001) than in MCF-7 cells that do not express PTN (34.7% of inhibition; P < 0.001).
PTN#111-136 Down-regulates the Expression of Genes Linked to Angiogenesis, Proliferation, and Apoptosis In vitro
The mRNA level from MDA-MB-231 cells and stably transfected MDA-MB-231-PTND111-136 cells was evaluated using real-time RT-PCR (Table 1) .
To obtain further evidence confirming the inhibition of angiogenesis, we examined the expression profile of genes involved in hypoxia and angiogenesis pathways, namely the VEGF and platelet-derived growth factor families and hypoxia-inducible factor (HIF-1a). Whereas VEGF-B, VEGF-C, platelet-derived growth factor-a, and plateletderived growth factor-h did not seem to be affected by PTND111-136 expression, VEGF-A and HIF-1a were significantly down-regulated by 59% and 71%, respectively, compared with levels in wild-type cells (P < 0.05).
We also examined the expression profiles of key proteins such as TOP2A and BCL2 and TNFAIP3/A20 (an antiapoptosis nuclear factor-nB pathway-associated gene), respectively, involved in proliferation and in cell protection against apoptosis. Significant down-regulation of mRNA levels of these three genes was observed: TOP2A expression was reduced by 64%, whereas BCL2 and TNFAIP3/ A20 expression was lowered by 72% and 73% (P < 0.05), respectively, in MDA-MB-231 cells expressing PTND111-136 compared with wild-type cells. In this study, p21/ CDKN1A and GADD45B mRNA levels involved in the apoptosis pathway were not affected.
Inhibition of Tumor Growth of PTN#111-136 In vivo PTN has been described previously to induce tumor formation in nude mice (2) . Hence, 4 Â 10 6 MDA-MB-231 human adenocarcinoma mammary cells expressing PTND111-136 were injected s.c. into nude mice and their tumorigenicity was compared with that of injected parental cells (n = 11 per group). Five days after injection, 100% of nude mice receiving nontransfected MDA-MB-231 cells started to develop small tumors that reached a mean volume of 608 F 3.8 mm 3 at day 33. In contrast, 5 days after the injection of MDA-MB-231 cells expressing PTND111-136, only 3 of 11 mice developed tiny tumors, which have completely disappeared after 10 days (Fig. 4A) . 
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We then conducted two other experiments to confirm the antitumor potency of PTND111-136 in a prophylactic protocol after muscle electrotransfer of the pcDNA3-PTND111-136 plasmid. We first electrotransferred 60 Ag pcDNA3PTND111-136 or pcDNA3-HSA (pcDNA3 control plasmid expressing human serum albumin) into the tibialis cranialis muscles of female nude mice (n = 10 per group). Seven days later, 4 Â 10 6 MDA-MB-231 cells were inoculated s.c.
To evaluate electrotransfer efficiency and to detect in vivo expression of PTND111-136, tibialis cranialis muscles of mice were collected at day 37 and analyzed by a specific ELISA. As shown in Fig. 4B , all muscle extracts, except one (mouse 7), exhibited a high amount of immunoreactive PTND111-136 that was not observed in the control group. The mean value of PTND111-136 was 1724 F 214 pg/mg tissue (range, 341-8,441 pg/mg). As shown in Fig. 4C , tumor growth in treated animals was significantly inhibited compared with tumor growth in animals in the control group: 37 days after electrotransfer, the tumor volumes were reduced by 60% (P < 0.0001). The tumors had reached a mean volume of 321 F 23 and 790 F 17 mm 3 in the pcDNA3-PTND111-136-injected and pcDNA3-HSAinjected groups, respectively. No toxicity of PTND111-136 could be observed after 37 days of treatment, and no significant difference (P = 0.15) in the weight of the mice could be observed in the completion of the first experiments: 31.8 F 1.8 versus 32.9 F 1.9 g, respectively, for the treated and control groups. To determine whether PTND111-136 produced after muscle electrotransfer targeted the tumor vasculature, we immunostained blood vessels in tumor tissue sections using an anti-CD31 antibody. Necrotic areas were excluded by microscopic examination, because microvasculature features may be artifactual in these regions. We observed a dramatic decrease in microvessel density in tumor tissues from animals expressing PTND111-136 compared with those from control animals (Fig. 4D) . We did a quantitative analysis of CD31 staining of tissue sections and found significantly different score indexes (P < 0.005) for the PTND111-136-expressing group (0.75 F 0.06) versus the control group (1.94 F 0.09), indicating a marked effect of the transgene product on the tumor vasculature. Interestingly, for mouse 7, which was negative for the PTND111-136 ELISA done on the muscle extract, we observed a high vessel index (2.69), showing good correlation between PTND111-136 expression in the muscle and the effect on the tumor vessel network.
We then conducted a second experiment, under the same conditions, except that only 40 Ag pcDNA3 plasmid expressing PTND111-136 or the pcDNA3-LacZ control plasmid expressing the h-galactosidase encoded by the Escherichia coli lacZ gene were electrotransferred. The efficiency of the electrotransfer was first evaluated at completion of the experiment (day 47) on muscle sections receiving the pcDNA3-LacZ plasmid expressing a nonsecreted molecule. As shown in Fig. 5A, 1 and 2 , a high level of h-galactosidase staining was observed only in the muscles of mice receiving the control plasmid confirming that plasmid electrotransfer in mouse muscles was significantly effective.
As shown in Fig. 5B, 3 and 4, MDA-MB-231 tumors from the PTND111-136-injected group were significantly smaller than those from the control group (P = 0.003) at day 47: tumors had reached a mean volume of 231.5 F 12 mm 3 for the pcDNA3-PTND111-136-treated mice versus 1127 F 93.5 mm 3 for control mice. This 80% inhibition correlated with the detection of a high amount (776 F 36 pg/mg tissue) of immunoreactive PTND111-136 in muscle extracts (Fig. 5B, 2) and sections (Figs. 5A, 5, and 6) assessed by ELISA and immunohistochemistry, respectively, and in tumor extracts (Fig. 5C, 1) , assessed by Western blot analysis following heparin Sepharose precipitation. PTN-immunoreactive material with a molecular weight of 18 kDa (lane 1) corresponding to native PTN molecule was detected in tumors from treated and nontreated animals. Furthermore, immunoreactive PTN with lower molecular weight corresponding to proteolytic fragments of PTN was detected in treated and nontreated mice with molecular weight of 15 kDa corresponding to PTND111-136 and fragments with molecular weight less than 15 and 10 kDa. These immunoreactive fragments corresponding to proteolytic degradation of PTN and/or PTND111-136 were found significantly increased by 42% and 57% in tumors from the treated mice. As shown in Fig. 5A, 3 and 4 , MDA-MB-231 tumors treated with PTND111-136 were very smaller and much less vascularized compared with untreated tumors.
During this experiment, tumor proliferative activity was assessed by means of Ki-67 immunostaining, which is now widely used in clinical pathology diagnostics. Collected tumor tissues were stained with anti-Ki-67 antibody and nonnecrotic areas on histologic slides were scored. The proliferation appeared to be significantly decreased in the group electrotransferred with pcDNA3-PTND111-136 compared with the control group (Figs. 5C, 2, and 5A, 7 and 8) .
According to the immunohistochemical analysis, the percentage of Ki-67-positive MDA-MB-231 cells was significantly reduced by 41% (P = 0.003).
We carried out an in vivo experiment, under the same conditions, using PC3 human prostate carcinoma cells; as shown, no significant difference was observed (P = 0.2) in tumor growth in either group (Fig. 5D) . 
Discussion
PTN is expressed in many human tumors and tumor cell lines including neuroblastoma, melanoma, pancreatic, lung, and breast cancers (29 -32) and can be a rate-limiting growth and an angiogenic factor in tumor development and metastasis in vivo (30) . This finding sparked off efforts to design technologies aimed at interfering with the PTN signaling pathway or with its receptors, thereby blocking tumor development and angiogenesis. Various strategies have been developed such as the use of ribozymes, RNA interference, or a monoclonal antibody to down-regulate PTN expression or that of its tyrosine kinase-linked receptors (33, 34) .
In the present study, we investigated a new strategy evaluating the antitumor effect of a truncated PTN lacking the COOH-terminal 111 to 136 portion of the molecule (PTND111-136), which is known to be involved in the mitogenic and in the transforming activities of this growth factor and in its binding to high-affinity receptors (2) .
The antiproliferative activity of PTND111-136 was first evaluated on tumor cell lines that express high and low level of PTN using MDA-MB-231 breast cells and PC3 prostate cell lines, respectively. Furthermore, we have evaluated PTND111-136 on breast MCF-7 cells that do not express PTN. In contrast to U87MG or U138MG cell lines, known to express ALK, all the three cell lines do not express ALK in our experimental settings cells and do not express all the RPTP receptors members. Whereas RPTPS seems to be ubiquitarily expressed in all the three cell lines, RPTPA and RPTPB are especially expressed by both breast tumors cells in contrast to PC3 prostatic cell line expressing only RPTPD.
We showed in our study that PTND111-136 was able to significantly reduce in vitro the proliferation of tumors cells that only expressed high levels of PTN as MDA-MB-231 breast-tumor cells. In this case, heterodimerization of the COOH-terminal mutant with endogenous PTN probably mainly explains its dominant-negative effect and that PTND111-136 was able to dissociate PTN homodimers, thereby inducing the formation of nonfunctional heterodimers. Thus, the inhibition of PTN in MDA-MB-231 cells has a wide effect on different important cellular systems. In this context, we believe that the inhibition of PTN by PTND111-136 abolishes the PTN/RPTPB signaling pathways independently of ALK, as it was suggested previously using human prostatic adenocarcinoma cells DU145 (14) . The RPTPB receptor was found to be involved in PTN-induced cell migration and neurite outgrowth (35) . Binding of PTN to RPTPB was shown to inactivate the catalytic phosphatase activity, leading to further activation of the Src/Fyn kinase family and h-catenin phosphorylation pathway (36) . In keeping with this hypothesis, we found that PTND111-136 did not affect the proliferation of PC3 cells and thus believe that the autocrine PTN signaling loop is very marginal because these cells do not exhibit high PTN level or the major cell surface tyrosine kinaselinked receptor such as ALK or RPTPB.
On the other hand, we have shown that PTND111-136 inhibited the in vitro growth of MCF-7 cells, expressing as MDA-MB-231 the same surface tyrosine kinase-linked receptors. MCF-7 cell line is known to express MDK and not PTN (37) ; therefore, we can conclude to the existence of an autocrine MDK signaling loop through the RPTPB receptor because high levels of MDK transcript were found for this cell line. In this context, we believe that PTND111-136 could induce the formation of nonfunctional heterodimers with MDK and thus inhibit the MDK/RPTPB pathway. MDK and PTN are members of the same neurotrophic family factors and are both basic, cysteinerich polypeptide containing identical heparin-binding motifs, which are essential for the dimerization of PTN (9) . They have about 50% of homology and no sequence homology with other heparin-binding proteins, such fibroblast growth factors. In this context, the formation of MDK/PTND111-136 heterodimers are not excluded and further experiments have to be conducted to explore this hypothesis.
Because angiogenesis is also known to be a key mechanism via which PTN promotes tumorigenesis (5), we investigated the effects of PTND111-136 endothelial cell proliferation and migration. We were able to show that the inhibition of PTN by PTND111-136 has major consequences on different stages of angiogenesis, because PTND111-136 strongly inhibited the proliferation and the migration of endothelial cells in vitro. Our in vitro results were confirmed in vivo, because tumor formation in nude mice usually obtained with MDA-MB-231 cells was completely abolished when PTND111-136-expressing MDA-MB-231 cells were injected, suggesting that both the growth advantage and the angiogenic activity were inhibited. Furthermore, we showed that PTND111-136-expressing MDA-MB-231 cells were not efficient in promoting VEGF-and HIF-1a-induced angiogenesis compared with MDA-MB-231 cells. Indeed, we determined by quantitative RT-PCR that PTND111-136 significantly down-regulated the expression of genes involved in hypoxia and the angiogenesis pathway such as VEGF-A as suggested previously (38) . Moreover, further experiments are warranted to explain these results and more particularly to explore the role of PTND111-136 in phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling, because the expression of HIF-1a and VEGF-A was recently shown to be dependent on the mammalian target of rapamycin pathway (39, 40) .
To complete and confirm our in vitro experiments, we investigated the antitumor efficacy and antiangiogenic properties of PTND111-136 using an in vivo therapeutic approach using intramuscular electrotransfer of a plasmid delivering a secretable form of PTND111-136. The longterm and durable expression of the molecule we observed reflects the quiescent status of the electrotransferred myofibers, thus showing that this method does not induce significant muscle damage, as confirmed at histologic examination (data not shown).
A single intramuscular injection of pcDNA3-PTND111-136 but not of the control plasmid was shown to dramatically inhibit primary tumor growth in two independent experiments, without apparent toxicity. This inhibitory effect was observed only with the MDA-MB-231 tumor xenografted in nude mice. These observations were correlated with the results of in vitro experiments and suggest that the inhibitory effects of PTND111-136 observed on MDA-MB-231 tumor growth seem to be exclusively a consequence of the inhibition of endogenous PTN. This antitumoral inhibitory effect was tightly correlated with markedly decreased vascularization within tumors and with the detection of PTND111-136 immunoreactive material in muscle sections and extracts together with the detection of high levels of immunoreactive materials in the tumor extracts corresponding to little peptides that could be produced from cleavage of PTND111-136 by extracellular proteolytic enzymes such as plasmin or matrix metalloproteinase-2, as it has been recently suggested (41, 42) . We also showed that PTND111-136 induced significant G 0 quiescence in a large fraction of MDA-MB-231 cells as revealed by Ki-67-positive immunostaining. Furthermore, we showed in vitro that genes promoting cellular proliferation and genes protecting against apoptosis were deregulated in PTND111-136-expressing MDA-MB-231 cells. We were able to show that the inhibition of PTN by PTND111-136 significantly downregulated the expression of TOP2A and the antiapoptosis genes BCL2 and TNFAIP3/A20, this latter gene being a well-known antiapoptosis nuclear factor-nB pathwayassociated gene.
In conclusion, we have shown that specific targeting of PTN by PTND111-136 involves strong inhibition of a breast tumor model and inhibition of the angiogenesis process. Nevertheless, the fact that cDNA muscle electrotransfer failed to completely abolish tumorigenesis underlines the importance of improving the gene transfer method, so that sustained expression can be achieved for maximum clinical benefits. We also intend to combine PTN inhibitors with cytotoxic approaches to enhance PTN inhibitor potency and thus improve the clinical outcome of patients with malignant diseases.
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